- Home
- ULCC vs MNMD Comparison
ULCC vs MNMD Comparison
Compare ULCC & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ULCC
- MNMD
- Stock Information
- Founded
- ULCC 1994
- MNMD 2019
- Country
- ULCC United States
- MNMD United States
- Employees
- ULCC N/A
- MNMD N/A
- Industry
- ULCC Air Freight/Delivery Services
- MNMD Pharmaceuticals and Biotechnology
- Sector
- ULCC Consumer Discretionary
- MNMD Health Care
- Exchange
- ULCC Nasdaq
- MNMD Nasdaq
- Market Cap
- ULCC 1.1B
- MNMD 960.2M
- IPO Year
- ULCC 2021
- MNMD N/A
- Fundamental
- Price
- ULCC $3.60
- MNMD $12.28
- Analyst Decision
- ULCC Hold
- MNMD Strong Buy
- Analyst Count
- ULCC 9
- MNMD 7
- Target Price
- ULCC $5.63
- MNMD $26.71
- AVG Volume (30 Days)
- ULCC 3.8M
- MNMD 2.3M
- Earning Date
- ULCC 11-05-2025
- MNMD 11-06-2025
- Dividend Yield
- ULCC N/A
- MNMD N/A
- EPS Growth
- ULCC N/A
- MNMD N/A
- EPS
- ULCC N/A
- MNMD N/A
- Revenue
- ULCC $3,778,000,000.00
- MNMD N/A
- Revenue This Year
- ULCC $1.14
- MNMD N/A
- Revenue Next Year
- ULCC $13.33
- MNMD N/A
- P/E Ratio
- ULCC N/A
- MNMD N/A
- Revenue Growth
- ULCC 4.60
- MNMD N/A
- 52 Week Low
- ULCC $2.89
- MNMD $4.70
- 52 Week High
- ULCC $10.26
- MNMD $14.43
- Technical
- Relative Strength Index (RSI)
- ULCC 37.74
- MNMD 49.99
- Support Level
- ULCC $4.11
- MNMD $12.60
- Resistance Level
- ULCC $3.88
- MNMD $14.43
- Average True Range (ATR)
- ULCC 0.25
- MNMD 1.00
- MACD
- ULCC -0.04
- MNMD -0.06
- Stochastic Oscillator
- ULCC 11.93
- MNMD 24.91
About ULCC Frontier Group Holdings Inc.
Frontier Group Holdings Inc is an ultra-low-cost carrier whose business is focused on Low Fares Done Right. The company owns a fleet of 120 Airbus single-aisle aircraft, consisting of 13 A320ceos, 82 A320neos, 21 A321ceos and 4 A321neos. The use of these aircraft, their seating configuration, weight-saving tactics, and baggage process have all contributed to the ability to continue to be the fuel-efficient of all the U.S. The Company is managed as a single business unit that provides air transportation for passengers. Majority of revenue is from Domestic flight follow by International.
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).